



Sheet 1 of 1

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 690068.575	APPLICATION NO. 10/797,927
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Val Goodfellow	
		FILING DATE March 8, 2004	GROUP ART UNIT 1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AP	AA	2002/0052383	05/02/02	Bakthavatchalam et al.	514	255.03	
	AB						
	AC						
	AD						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
AP	AE	WO 01/21169 A1	03/29/01	WIPO		
	AF	WO 01/21577 A2	03/29/01	WIPO		
	AG	2001-226269	08/21/01	JP (+ Abstract in English)		
	AH	WO 01/82925 A1	11/08/01	WIPO		
	AI	WO 01/87834 A1	11/22/01	WIPO		
	AJ	WO 01/94368 A1	12/13/01	WIPO		
	AK	WO 02/04433 A2	01/17/02	WIPO		
	AL	WO 02/06245 A1	01/24/02	WIPO		
	AM	WO 02/059108 A1	08/01/02	WIPO		
	AN	WO 02/070511 A1	09/12/02	WIPO		
AP	AO	WO 03/031410 A1	04/17/03	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	AP	Bednarek, M., et al., "Synthesis and Biological Evaluation in Vitro of a Selective, High Potency Peptide Agonist of Human Melanin-concentrating Hormone Action at Human Melanin-concentrating Hormone Receptor 1," <i>J. Biol. Chem.</i> 277(16):13821-6, April 19, 2002.
AP	AQ	Takekawa, S., et al., "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist," <i>Eur J Pharmacol.</i> 438(3):129-35, March 8, 2002.

EXAMINER /Alton Pryor/	DATE CONSIDERED (09/16/2006)
---------------------------	---------------------------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).